Why the study?
Differential diagnosis of PH associated with left heart disease versus PAH is challenging, especially in patients with cardiovascular comorbidities or HFpEF, and there is currently no approved therapy.
This review highlights the diagnostic challenges of PH associated with left heart disease and emphasizes that treatment must focus on the underlying condition rather than PAH-specific therapies.
No takes yet. Share an insight, caveat, or question.
Highlights need for careful PH phenotyping in HF; leaves open optimal strategies for mixed pre-/post-capillary PH and RV involvement.
Baratto et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: